Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: BigAppleBoy who wrote (2933)	8/2/1999 11:49:00 AM
From: BARRY ALLEN	Respond to of 4140

Ticker Company Name Month Shares Short Avg Daily Volume Ratio* SNRS Sunrise Technologies International Inc. 07/99 7,149,538 1,993,801 3.59 06/99 4,369,160 736,457 5.93 05/99 3,227,585 637,596 5.06 04/99 2,648,862 438,660 6.04 03/99 2,271,143 429,756 5.28 02/99 2,103,658 1,040,770 2.02 * Ratio = Shares Short / Avg Daily Volume; it may be used as a rough measure of days to cover. viwes.com

To: BigAppleBoy who wrote (2933)	8/2/1999 11:53:00 AM
From: BARRY ALLEN	Respond to of 4140

By: reflect Reply To: None Monday, 2 Aug 1999 at 9:51 AM EDT Post # of 14635 Notification of Representatives Many posters have already informed this board that they have notified their elected representatives. At this time, I am appealing to all stockholders, as well as non-stockholders who believe LTK is an important product, to write to both their congressional representative and their senators. The reason I believe this is important is because I do not believe snrs is playing on a level playing field. Notification of representatives is one way to ensure a level playing field. Enclosed below is the letter I have sent to my congressional representative. Feel free to base your letter on it, but don't copy it because elected representatives hate form letters and give less credence to them. For all of you physicians out there, especially the ophthmalogists, put a notice in your waiting room encouraging your patients to support LTK and write their elected representatives. You may note in my letter that I merely request the FDA conduct a fair evaluation of LTK. I am not asking my representative to ensure approval of LTK because I believe it is the FDA's responsibilitiy to evaluate LTK and make a decision. For those of you who do not know who their representatives are, simply look in the phone book under the United States Government and you should find names, address and telephone numbers of your representatives. You can also call your local library for the information. You can keep it simple - a short two sentence letter will suffice. I know there are a ton of people out there who read this board and seldom, if ever, contribute to it. To all of you people, take a few minutes and write these important letters. Bill McCollum United States House of Representatives 8th District 605 E. Robinson Street Suite 650 Orlando, FL 32801 Dear Congressman McCollum: I write this letter as a very concerned citizen and fellow Republican. There is a new medical procedure called Laser Thermal Keratoplasty (LTK) which the FDA is currently reviewing for approval. LTK treats hyperopia (far-sightedness) and presbyopia (age related loss of near focusing ability). It is a safe and effective procedure that uses a laser. The primary advantages of LTK are that it is i) effective; ii) non-invasive; and iii) safe. Sunrise Technologies International, Inc. of Fremont, California holds the patent procedure for LTK. As part of a multi-step process, Sunrise went before an Ophthalmic Devices Panel (ODP) on July 22, 1999. The purpose of this panel was to review LTK data and make a recommendation to the FDA regarding approval. The ODP conducted a hearing on July 22, 1999. After the hearing the ODP announced the ODP would not recommend approval to the FDA at this time. The ODP found LTK to be a very safe procedure. The ODP also found Sunrise's study had great accountability (number of patients tracked post-operatively). However, the ODP found that Sunrise had not shown conclusively that LTK is effective. The ODP's finding concerning LTK's effectiveness is nonsense. At the panel hearing Sunrise presented conclusive evidence based on case studies that LTK is effective. After thoroughly reviewing th ODP's findings and statements, I simply do not understand the ODP's reasons for their recommendation of approval denial. The next step in this process is actual FDA action. The FDA sometimes agrees with their panel's findings and sometimes disagrees with their panel's findings. Sunrise, who also strongly disagrees with the ODP's findings, is currently in contact with the FDA regarding further FDA direction. The purpose of this letter is to ask your support in assuring the FDA undertakes a fair and full evaluation of LTK. I don't believe the ODP conducted a fair and full evaluation of LTK. I further believe the ODP blind-sided Sunrise at the ODP meeting and requested meaningless data that simply was not part of the FDA criteria. The LTK procedure will help correct the vision of millions of far-sighted Americans. Floridians will especially benefit from this procedure, given our demographics. I am very concerned about the inhibition of a new and important medical procedure in this country. As my Congressman, I ask that you look into this matter. Again, all I ask is an assurance that the FDA does a fair and full evaluation of LTK. Thank you. ragingbull.com